Don't view AI as just a feature set. Instead, treat "intelligence" as a fundamental new building block for software, on par with established primitives like databases or APIs. When conceptualizing any new product, assume this intelligence layer is a non-negotiable part of the technology stack to solve user problems effectively.

Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

Powerful AI models for biology exist, but the industry lacks a breakthrough user interface—a "ChatGPT for science"—that makes them accessible, trustworthy, and integrated into wet lab scientists' workflows. This adoption and translation problem is the biggest hurdle, not the raw capability of the AI models themselves.

Instead of selling software to traditional industries, a more defensible approach is to build vertically integrated companies. This involves acquiring or starting a business in a non-sexy industry (e.g., a law firm, hospital) and rebuilding its entire operational stack with AI at its core, something a pure software vendor cannot do.

The next evolution in personalized medicine will be interoperability between personal and clinical AIs. A patient's AI, rich with daily context, will interface with their doctor's AI, trained on clinical data, to create a shared understanding before the human consultation begins.

The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

CZI’s mission to cure all diseases is seen as unambitious by AI experts but overly ambitious by biologists. This productive tension forces biologists to pinpoint concrete obstacles and AI experts to grasp data complexity, accelerating the overall pace of innovation.

CZI's New York Biohub is treating the immune system as a programmable platform. They are engineering cells to navigate the body, detect disease markers like heart plaques, record this information in their DNA, and then be read externally, creating a living diagnostic tool.

Instead of building a single-purpose application (first-order thinking), successful AI product strategy involves creating platforms that enable users to build their own solutions (second-order thinking). This approach targets a much larger opportunity by empowering users to create custom workflows.